{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:19Z","timestamp":1761895939672},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":375,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Dermatol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1111\/ced.12388","type":"journal-article","created":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T15:35:19Z","timestamp":1408721719000},"page":"791-794","source":"Crossref","is-referenced-by-count":5,"title":["Multiple squamous cell carcinomas following introduction of nilotinib"],"prefix":"10.1093","volume":"39","author":[{"given":"P.","family":"Peters","sequence":"first","affiliation":[{"name":"Queensland Institute of Dermatology; Brisbane QLD Australia"},{"name":"School of Medicine; University of Queensland; Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Rabbolini","sequence":"additional","affiliation":[{"name":"University of Queensland Diamantina Institute; Translational Research Institute; Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sinnya","sequence":"additional","affiliation":[{"name":"Queensland Institute of Dermatology; Brisbane QLD Australia"},{"name":"Haematology Department; The Canberra Hospital; Canberra ACT Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Khosrotehrani","sequence":"additional","affiliation":[{"name":"Queensland Institute of Dermatology; Brisbane QLD Australia"},{"name":"Haematology Department; The Canberra Hospital; Canberra ACT Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Queensland Institute of Dermatology; Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"10.1111\/ced.12388-BIB0001|ced12388-cit-0001","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/1040-8428(96)00192-8","article-title":"Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches","volume":"22","author":"Ferrajoli","year":"1996","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/ced.12388-BIB0002|ced12388-cit-0002","first-page":"63","article-title":"Targeted treatment of chronic myeloid leukemia: role of imatinib","volume":"2","author":"Tamascar","year":"2009","journal-title":"Onco Targets Ther"},{"key":"10.1111\/ced.12388-BIB0003|ced12388-cit-0003","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1111\/ced.12388-BIB0004|ced12388-cit-0004","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1111\/ced.12388-BIB0005|ced12388-cit-0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1001\/archderm.144.3.361","article-title":"Bullous sweet syndrome in a patient with t(9;22) (q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL-positive lesional cells","volume":"144","author":"Kaune","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1111\/ced.12388-BIB0006|ced12388-cit-0006","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/ced.12388-BIB0007|ced12388-cit-0007","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":"Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1111\/ced.12388-BIB0008|ced12388-cit-0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1111\/ced.12388-BIB0009|ced12388-cit-0009","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1111\/ced.12388-BIB0010|ced12388-cit-0010","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"10.1111\/ced.12388-BIB0011|ced12388-cit-0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1034\/j.1600-0609.2003.00044.x","article-title":"Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment","volume":"70","author":"Baskaynak","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1111\/ced.12388-BIB0012|ced12388-cit-0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2340\/00015555-0368","article-title":"Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment","volume":"88","author":"Kawakami","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/ced.12388-BIB0013|ced12388-cit-0013","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/dsu.12184","article-title":"Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma","volume":"39","author":"Breaker","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.1111\/ced.12388-BIB0014|ced12388-cit-0014","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdv.12172","article-title":"Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience","volume":"27","author":"Brazzelli","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/ced.12388-BIB0015|ced12388-cit-0015","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1529-8019.2011.01431.x","article-title":"Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib","volume":"24","author":"Amitay-Laish","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1111\/ced.12388-BIB0016|ced12388-cit-0016","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2013.07.025","article-title":"Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia","volume":"69","author":"Delgado","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/ced.12388-BIB0017|ced12388-cit-0017","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/ced.12388-BIB0018|ced12388-cit-0018","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1538-7445.AM2013-4095","article-title":"Paradoxical activation of the RAF-MEK-ERK pathway in response to nilotinib induces synthetic lethality with MEK inhibition in head and neck cancer cells","volume":"73","author":"Sen","year":"2013","journal-title":"Cancer Res"},{"key":"10.1111\/ced.12388-BIB0019|ced12388-cit-0019","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4161\/cc.8.9.8308","article-title":"BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma","volume":"8","author":"Zaravinos","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1111\/ced.12388-BIB0020|ced12388-cit-0020","unstructured":"Novartis Pharmaceuticals Approved product information for nilotinib 2008"},{"key":"10.1111\/ced.12388-BIB0021|ced12388-cit-0021","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/sj.bjc.6605868","article-title":"Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib","volume":"103","author":"Flaig","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1111\/ced.12388-BIB0022|ced12388-cit-0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3816\/CGC.2009.n.003","article-title":"Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib","volume":"7","author":"Dubauskas","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1111\/ced.12388-BIB0023|ced12388-cit-0023","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/j.1365-4632.2012.05485.x","article-title":"Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma","volume":"52","author":"Tal","year":"2013","journal-title":"Int J Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fced.12388","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ced.12388\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:39:40Z","timestamp":1676385580000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/39\/7\/791\/6621292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1111\/ced.12388","relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}